Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

by NASDAQ Market News June 26, 2020

NASDAQ Market News
Click here to email author

NuGenerex Immuno-Oncology Announces Shareholder Conference Call July 10, 2020 at 4:15 PM

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Ads